Jonathan A. Meulbroek
AbbVie (United States)(US)
Publications by Year
Research Areas
NF-κB Signaling Pathways, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, Advanced Drug Delivery Systems
Most-Cited Works
- → ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models(2007)764 cited
- → Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches(1990)687 cited
- → Biodegradable microspheres as a vaccine delivery system(1991)395 cited
- → Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies(1991)369 cited
- → Biodegradable Microspheres: Vaccine Delivery System for Oral Immunization(1989)194 cited
- → ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope(2016)179 cited
- → Vaccine-Containing Biodegradable Microspheres Specifically Enter the Gut-Associated Lymphoid Tissue Following Oral Administration and Induce a Disseminated Mucosal Immune Response(1989)134 cited
- → Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3-β-glucosyltransferase(1997)98 cited
- → Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody(2015)81 cited
- → Synthesis and Structure−Activity Relationships of 2-Pyridones: A Novel Series of Potent DNA Gyrase Inhibitors as Antibacterial Agents(1996)75 cited